Trethera

Trethera is pioneering a novel therapeutic approach by inhibiting the deoxycytidine kinase (dCK) enzyme within the nucleotide salvage pathway, a metabolic process critical for the rapid proliferation of abnormal cells in cancer and autoimmunity. Its lead candidate, TRE-515, has demonstrated favorable safety and biomarker engagement in an initial Phase 1a solid tumor trial and holds FDA Orphan Drug Designation for two indications, positioning it for potential accelerated development. Backed by a team with a proven track record in drug discovery and company building, and supported by non-dilutive NIH grant funding, Trethera is advancing a single-molecule, multi-indication pipeline with a patient-centric focus.

Targeting the nucleotide salvage pathway via inhibition of the rate-limiting enzyme deoxycytidine kinase (dCK) to selectively starve rapidly proliferating diseased cells.

Direct competition targeting dCK is currently minimal, making TRE-515 a true first-in-class agent. However, it competes indirectly with a vast array of approved and investigational therapies in solid tumors and autoimmune diseases, including chemotherapies, targeted therapies, immunotherapies, and biologics. Its key differentiator is the novel metabolic mechanism aimed at achieving efficacy with potentially fewer side effects.